Unknown

Dataset Information

0

The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53.


ABSTRACT: Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively target and kill cancer cells while sparing normal ones. Among them, engineered Herpes simplex virus type 1 (HSV-1) has been proposed as a potential treatment for cancer and was moved to phase III clinical trials. Previous studies showed that design of OV therapy combined with p53 gene therapy increases the anti-cancer activities of OVs. Here, the UL39 gene of the ICP34.5 deleted HSV-1 was manipulated with the insertion of the EGFP-p53 expression cassette utilizing CRISPR/ Cas9 editing approach to enhance oncoselectivity and oncotoxicity capabilities. The ΔUL39/Δγ34.5/HSV1-p53 mutant was isolated using the chorioallantoic membrane (CAM) of fertilized chicken eggs as a complementing membrane to support the growth of the viruses with gene deficiencies. Comparing phenotypic features of ΔUL39/Δγ34.5/HSV1-p53-infected cells with the parent Δγ34.5/HSV-1 in vitro revealed that HSV-1-P53 had cytolytic ability in various cell lines from different origin with different p53 expression rates. Altogether, data presented here illustrate the feasibility of exploiting CAM model as a promising strategy for isolating recombinant viruses such as CRISPR/Cas9 mediated HSV-1-P53 mutant with less virus replication in cell lines due to increased cell mortality induced by exogenous p53.

SUBMITTER: Kelishadi M 

PROVIDER: S-EPMC10588894 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53.

Kelishadi Mishar M   Shahsavarani Hosein H   Tabarraei Alijan A   Shokrgozar Mohammad Ali MA   Teimoori-Toolabi Ladan L   Azadmanesh Kayhan K  

PloS one 20231020 10


Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively target and kill cancer cells while sparing normal ones. Among them, engineered Herpes simplex virus type 1 (HSV-1) has been proposed as a potential treatment for cancer and was moved to phase III clinical trials. Previous studies showed that design of OV therapy combined with p53 gene therapy increases the anti-cancer activities of OVs. Here, the UL39 gene of the ICP34.5 deleted HSV-1 was manipulated wit  ...[more]

Similar Datasets

| S-EPMC4822141 | biostudies-literature
| PRJEB32151 | ENA
| S-EPMC5480115 | biostudies-literature
| S-EPMC6881331 | biostudies-literature
| S-EPMC5848616 | biostudies-literature
| S-EPMC10432839 | biostudies-literature
| S-EPMC6008848 | biostudies-literature
| S-EPMC4910870 | biostudies-literature
| S-EPMC7406498 | biostudies-literature
| S-EPMC4460908 | biostudies-other